Management of stage II seminoma

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 290-294

  Warde, P ^a   Gospodarowicz, M ^a   Panzarella, T ^a   Catton, C ^a   Sturgeon, J ^a   Moore, M ^a   Jewett, M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PARAAORTIC LYMPH NODE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SEMINOMA;

EID: 0031982535     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.290     Document Type: Article

References (18)

1. Horwich A: Chemotherapy of seminoma. Eur Urol 2:26-28, 1993
2. Thomas G, Jones W, VanOosterom A, et al: Consensus statement on the investigation and management of testicular seminoma 1989. Prog Clin Biol Res 357:285-294, 1990
3. Gospodarowicz MK, Thomas GT, Sturgeon JFG: The optimal treatment of patients with stage II seminoma with moderate size retroperitoneal metastases (5-10 cm). Curr Opin Urol 1:76-79, 1991
4. Dosmann MA, Zagars GK: Post-orchiectomy radiotherapy for stages I and II testicular seminoma. Int J Radiat Oncol Biol Phys 26:381-390, 1993
5. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc 53:457-481, 1958
6. Mantel N: Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
7. Cox D: Regression models and life-tables. J Royal Statist Soc 34:187-220, 1972
8. Thomas GM, Rider WD, Dembo AJ, et al: Seminoma of the testis: Results of treatment and patterns of failure after radiation therapy. Int J Radiat Oncol Biol Phys 8:165-174, 1982
9. Mencel PJ, Motzer RJ, Mazumdar M, et al: Advanced seminoma: Treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 12:120-126, 1994
10. Steinfeld A, Newall J: Controversies in management of stages I and II testicular seminomas. Urology 31:202-206, 1988
11. Thomas GM: Stage I, II seminoma - Then and now. Int J Radiat Oncol Biol Phys 26:545-546, 1993 (editorial)
12. Vallis K, Howard G, Duncan W, et al: Radiotherapy for stages I and II testicular seminoma: Results and morbidity in 238 patients. Br J Radiol 68:400-405, 1995
13. Yao WQ, Fossa SD, Dearnaley DP, et al: Combined single course carboplatin with radiotherapy in treatment of stage IIA, B seminoma - A preliminary report. Radiother Oncol 33:88-90, 1994
14. Bajorin DF, Sarosdy MF, Pfister DG, et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good risk germ cell tumors; A multi-institutional study. J Clin Oncol 11:598-606, 1993
15. Horwich A, Sleijfer D, Fossa S, et al: A trial of carboplatin-based combination chemotherapy in good prognosis metastatic testicular nonseminoma. Proc Am Soc Clin Oncol 13:230, 1994
16. Horwich A, Dearnaley DP, A'Hern R, et al: The activity of single-agent carboplatin in advanced seminoma. Eur J Cancer 28A:1307-1310, 1992
17. Herr HW, Sheinfeld J, Pue HS, et al: Surgery for a post-chemotherapy residual mass in seminoma. J Urol 157:860-862, 1997
18. Culine S, Droz JP: Optimal management of residual mass after chemotherapy in advanced seminoma: There is time for everything. J Clin Oncol 14:2884-2885, 1996